Assessing the change in disease severity based on depressive symptoms in real-world psoriasis patients

J Comp Eff Res. 2021 Nov;10(16):1215-1224. doi: 10.2217/cer-2021-0106. Epub 2021 Sep 29.

Abstract

Aim: To evaluate whether the presence of a history of depression hinders psoriasis response to systemic therapies and to delineate baseline characteristics of patients whose depressive symptoms improved on systemic treatment. Methods: We studied patients within the Corrona® Psoriasis Registry, a prospective, multicenter observational disease-based registry, that were enrolled through September 2018, comparing changes from enrollment to 12-month visit. Results: There was a statistically significant improvement in all disease characteristics and most patient-reported outcomes in patients reporting a history of depression and in those that did not while there was no statistically significant difference in the degree of change comparing these two cohorts. Patients who noted improvement in depressive symptoms had more severe baseline disease characteristics and reported overall worse baseline patient-reported outcomes. Conclusions: History of depression does not portend a differential response to systemic treatment. Patients with improvement in depressive symptoms had worse baseline characteristics.

Keywords: biologics; depression; disease severity; nonbiologic systemics; patient-reported outcomes; psoriasis.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Depression* / epidemiology
  • Humans
  • Patient Reported Outcome Measures
  • Prospective Studies
  • Psoriasis* / drug therapy
  • Registries
  • Severity of Illness Index